The United States Food and Drug Administration and the end of antibiotics

David M Shlaes et al. Clin Infect Dis. 2002.

. 2002 Feb 1;34(3):420-2.

doi: 10.1086/338976.

No abstract available

Comment in

The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents.
Powers JH, Ross DB, Brittain E, Albrecht R, Goldberger MJ. Powers JH, et al. Clin Infect Dis. 2002 Mar 15;34(6):879-81. doi: 10.1086/339803. Clin Infect Dis. 2002. PMID: 11850875 No abstract available.
Is there hope for the prevention of future antimicrobial shortages?
Gilbert DN, Edwards JE Jr. Gilbert DN, et al. Clin Infect Dis. 2002 Jul 15;35(2):215-6; author reply 216-7. doi: 10.1086/341958. Clin Infect Dis. 2002. PMID: 12087536 No abstract available.
A response to strategy #2: streamlining the regulatory process.
Glezen WP. Glezen WP. Clin Infect Dis. 2006 Mar 1;42 Suppl 3:S141-4. doi: 10.1086/499594. Clin Infect Dis. 2006. PMID: 16447137